Discourage Using the New Oral Antiplatelet Drug Zontivity Alone
You'll hear controversy about the new oral antiplatelet drug, Zontivity (zon-TIV-i-tee, vorapaxar).
It's the first protease-activated receptor-1 (PAR-1) antagonist...and inhibits platelet aggregation for about 4 weeks.
It's approved for use with low-dose aspirin and/or clopidogrel after a heart attack or in patients with peripheral artery disease...to further reduce CV events or death.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote